Healthcare

The biotech sector struggled throughout the latter half of 2016, as markets priced in expectations of a Democratic term in the White House, and what this might mean for drug pricing. Forced lower pricing would reduce big name investment, and this could hurt the smaller companies' potential to expand...

Barry Honig is one of the biotech space's most renowned entrepreneurs and investors. Along with his compatriot, Dr. Phillip Frost, he has been responsible for some of the big name successes in the sector. Many investors like to piggyback his positions, so here's one he just announced. In a just...

Interpace Diagnostics Group Inc (NASDAQ:IDXG) shares jumped 70.45% to $7.50 on Tuesday then retreated 10% in after-hours trading to $6.75. The company has a market cap of $12.10 million at 2.02 million shares outstanding. Share prices have been trading in a 52-week range of $0.70 to $19.80. Formerly known as...

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) reported that Plx Pharma Inc. has picked up 4,414,270 of common stock as of 2017-01-03. The acquisition brings the aggregate amount owned Plx Pharma Inc. to a total of 4,414,270 representing...

We've been watching the medical space closely recently, and a recent share acquisition has just hit press that highlights the activity in the sector. Here's what's important, and what it means. In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Neogenomics Inc (NASDAQ:NEO) reported that...